TLX301

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals is a global leader in radiopharmaceuticals, focusing on theranostics—a combined diagnostic and therapeutic approach for cancer. The company has achieved commercial success with its FDA-approved prostate cancer imaging agent, Illuccix®, and is advancing a deep clinical pipeline targeting renal, brain, and other cancers. With a vertically integrated platform spanning discovery to commercialization, Telix is strategically positioned to capture significant value in the high-growth precision oncology market.

Therapeutic Areas